Free Trial
→ A free stock pick, from me to you (From Behind the Markets) (Ad)tc pixel
OTCMKTS:EFTR

eFFECTOR Therapeutics Earnings Date & Estimates

eFFECTOR Therapeutics logo
$0.0008 0.00 (0.00%)
As of 11/9/2026

eFFECTOR Therapeutics is estimated to report earnings on Tuesday, November 17, 2026.

Research:Profile

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from eFFECTOR Therapeutics

eFFECTOR Therapeutics is expected to post earnings of -$6.3960 per share on revenue of $100 thousand. eFFECTOR Therapeutics last reported on May 9, 2024, posting -$2.16 per share and beating the -$2.17 consensus estimate. eFFECTOR Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$6.3960
Expected Revenue
$100 thousand

Recent Track Record

Last Reported
Q1 2024
Last Quarter EPS
-$2.16 (Beat by +$0.01)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Earnings Call

eFFECTOR Therapeutics Earnings FAQ

eFFECTOR Therapeutics (OTCMKTS:EFTR) is estimated to report earnings on Tuesday, November 17, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect eFFECTOR Therapeutics to post earnings of -$6.3960 per share for the quarter.

The consensus revenue estimate for eFFECTOR Therapeutics is $100 thousand for the quarter.

eFFECTOR Therapeutics Earnings Headlines

EFTR - eFFECTOR Therapeutics, Inc.
September 25, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/EFTR
eFFECTOR Therapeutics (OTC:EFTR) Stock, Insider Trading Activity
October 5, 2024  |  benzinga.comhttps://www.benzinga.com/quote/EFTR/insider-trades
My prediction for December 8th
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
July 15, 2024  |  investorplace.comhttps://investorplace.com/2024/07/3-publicly-traded-companies-filing-for-bankruptcy-as-july-kicks-off/
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
June 24, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/24/2902850/0/en/effector-therapeutics-announces-it-will-wind-down-operations-as-it-seeks-strategic-alternatives-and-expects-to-be-delisted-from-nasdaq.html
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
May 20, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/20/2884841/0/en/effector-therapeutics-to-collaborate-with-the-dana-farber-cancer-institute-on-an-investigator-sponsored-phase-2-clinical-trial-evaluating-zotatifin-as-combination-treatment-in-er-e.html
See More eFFECTOR Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like eFFECTOR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on eFFECTOR Therapeutics and other key companies, straight to your email.

About eFFECTOR Therapeutics

eFFECTOR Therapeutics (OTCMKTS:EFTR) is a clinical-stage biopharmaceutical company focused on developing medicines that regulate protein production within cancer cells. Its approach, known as translation control, is designed to interfere with the mechanisms cancer cells use to produce proteins needed for growth, survival and resistance to treatment.

The company’s investigational pipeline has included zotatifin (eFT226), an inhibitor of the eukaryotic initiation factor 4A (eIF4A), and tomivosertib (eFT508), an inhibitor of mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1/2). These programs have been studied as potential treatments for solid tumors and other cancers, both as standalone therapies and in combination with existing treatments.

Founded in 2012 and headquartered in San Diego, California, eFFECTOR has operated primarily as a research and development company serving the oncology biopharmaceutical market. The company was led by co-founder Steven A. Worland, who has served as president and chief executive officer. Its therapies remain investigational and are subject to clinical development and regulatory review.

View eFFECTOR Therapeutics Profile
Earnings Tools